avapro and sq 28603
avapro has been researched along with sq 28603 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
| Fox, M; Panchal, BC; Trippodo, NC | 1 |
Reviews
1 review(s) available for avapro and sq 28603
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
Other Studies
1 other study(ies) available for avapro and sq 28603
| Article | Year |
|---|---|
Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
Topics: Alanine; Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Blood Volume; Bradykinin; Cricetinae; Drug Synergism; Enalaprilat; Heart Failure; Irbesartan; Male; Neprilysin; Tetrazoles; Vasodilation; Ventricular Function, Left | 1995 |